BRPI0717058A2 - Composto, composição farmacêutica, método para tratar, prevenir, inibir ou suprimir uma condição inflamatória ou doença ou doenças do sistema nervoso central e método para a preparação de um composto - Google Patents

Composto, composição farmacêutica, método para tratar, prevenir, inibir ou suprimir uma condição inflamatória ou doença ou doenças do sistema nervoso central e método para a preparação de um composto Download PDF

Info

Publication number
BRPI0717058A2
BRPI0717058A2 BRPI0717058-0A2A BRPI0717058A BRPI0717058A2 BR PI0717058 A2 BRPI0717058 A2 BR PI0717058A2 BR PI0717058 A BRPI0717058 A BR PI0717058A BR PI0717058 A2 BRPI0717058 A2 BR PI0717058A2
Authority
BR
Brazil
Prior art keywords
compound
azaspiro
dioxa
difluoromethoxy
formula
Prior art date
Application number
BRPI0717058-0A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Sonali Rudra
Nidhi Gupta
Lalit Kumar Baregama
Ritu Agarwal
Vinayak Vasantrao Khairnar
Saswati Chakladar
Mandadapu Raghu Ramaiah
Nagarajan Muthukamal
Sarla Balachandran
Sarika Ramnani
Venkata P Palle
Sunanda G Dastidar
Lalitha Vijaykrishnan
Jitendra Sattigeri
Abhijit Ray
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of BRPI0717058A2 publication Critical patent/BRPI0717058A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0717058-0A2A 2006-09-22 2007-09-22 Composto, composição farmacêutica, método para tratar, prevenir, inibir ou suprimir uma condição inflamatória ou doença ou doenças do sistema nervoso central e método para a preparação de um composto BRPI0717058A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2097DE2006 2006-09-22
IN2097/DEL/2006 2006-09-22
PCT/IB2007/053854 WO2008035315A2 (en) 2006-09-22 2007-09-22 Inhibitors of phosphodiesterase type-iv

Publications (1)

Publication Number Publication Date
BRPI0717058A2 true BRPI0717058A2 (pt) 2013-10-15

Family

ID=39200943

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0717058-0A2A BRPI0717058A2 (pt) 2006-09-22 2007-09-22 Composto, composição farmacêutica, método para tratar, prevenir, inibir ou suprimir uma condição inflamatória ou doença ou doenças do sistema nervoso central e método para a preparação de um composto

Country Status (11)

Country Link
US (1) US20110021473A1 (enExample)
EP (1) EP2086948A2 (enExample)
JP (1) JP2010504323A (enExample)
KR (1) KR20090069309A (enExample)
CN (1) CN101616901A (enExample)
AU (1) AU2007298549A1 (enExample)
BR (1) BRPI0717058A2 (enExample)
CA (1) CA2664247A1 (enExample)
EA (1) EA200900472A1 (enExample)
MX (1) MX2009003100A (enExample)
WO (1) WO2008035315A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006305620A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
DK2691379T3 (en) 2011-03-31 2017-02-13 Bayer Ip Gmbh HERBICID AND FUNGICID ACTIVE 3-PHENYLISOXAZOLINE-5-CARBOXAMIDES AND 3-PHENYLISOXAZOLIN-5-THIOAMIDES
BR112015006573B1 (pt) 2012-09-25 2020-11-03 Bayer Cropscience Ag derivados de 3-fenilisoxazolina, compoisições herbicidas, seus usos, e método para controle de plantas indesejáveis
EP2907806A1 (en) * 2014-02-14 2015-08-19 Universita Degli Studi Di Genova New compounds as selective PDE4D inhibitors
CN105085428B (zh) * 2014-04-25 2019-03-22 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
EA202090018A1 (ru) 2017-06-13 2020-05-26 Байер Акциенгезельшафт Гербицидно-активные 3-фенилизоксазолин-5-карбоксамиды тетрагидро- и дигидрофурановых карбоксамидов
SI3638665T1 (sl) 2017-06-13 2021-11-30 Bayer Aktiengesellschaft Herbicidni 3-fenilizoksazolin-5-karboksamidi tetrahidro in dihidrofuran karboksilnih kislin in estrov
EP3668845B1 (de) 2017-08-17 2024-06-26 Bayer Aktiengesellschaft Herbizid wirksame 3-phenyl-5-trifluormethylisoxazolin-5-carboxamide von cyclopentylcarbonsäuren und -estern
EP3743411B1 (de) 2018-01-25 2022-12-21 Bayer Aktiengesellschaft Herbizid wirksame 3-phenylisoxazolin-5-carboxamide von cyclopentenylcarbonsäurederivaten
CN108976107B (zh) * 2018-08-23 2021-03-23 南方医科大学 3-芳基-4-烷氧基苄胺衍生物及其制备方法和应用
CA3133025A1 (en) 2019-03-12 2020-09-17 Bayer Aktiengesellschaft Herbicidally active 3-phenylisoxazoline-5-carboxamides of s-containing cyclopentenyl carboxylic acid esters

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1047518A (en) * 1963-06-11 1966-11-02 Glaxo Lab Ltd 17ª‡-monoesters of 11,17,21-trihydroxy steroid compounds
NL128816C (enExample) * 1965-04-22
GB1158492A (en) * 1966-02-09 1969-07-16 Boots Pure Drug Co Ltd Improvements in Acylated Steroids
GB1200886A (en) * 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
US3937838A (en) * 1966-10-19 1976-02-10 Aktiebolaget Draco Orally active bronchospasmolytic compounds and their preparation
US3639434A (en) * 1967-02-02 1972-02-01 Boots Pure Drug Co Ltd 17-acyloxysteroids and their manufacture
US3780177A (en) * 1967-06-16 1973-12-18 Warner Lambert Co 17-butyrate,21-ester derivatives of 6alpha,9alpha-difluoroprednisolone,compositions and use
CH513845A (de) * 1967-11-17 1971-10-15 Ciba Geigy Ag Verfahren zur Herstellung neuer Halogenpregnadiene
GB1253831A (en) * 1968-01-19 1971-11-17 Glaxo Lab Ltd 9alpha,21-DIHALOPREGNANE COMPOUNDS
US3700681A (en) * 1971-02-16 1972-10-24 Pfizer 2-hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-aminoethyl)pyridines
US3947478A (en) * 1972-01-12 1976-03-30 Akzona Incorporated Alkylated 3,20-diketo-Δ4 -steroids of the pregnane series
US3994974A (en) * 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
SE378110B (enExample) * 1972-05-19 1975-08-18 Bofors Ab
US3992534A (en) * 1972-05-19 1976-11-16 Ab Bofors Compositions and method of treating with component B of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steriods
SE378109B (enExample) * 1972-05-19 1975-08-18 Bofors Ab
US4098804A (en) * 1973-05-30 1978-07-04 Jouveinal S.A. Esters of 21-thiol prednisone and prednisolone
FR2231374B1 (enExample) * 1973-05-30 1976-10-22 Jouveinal Sa
US4011258A (en) * 1973-06-21 1977-03-08 Aktiebolaget Draco Orally active bronchospasmolytic compounds
ZA744259B (en) * 1973-08-17 1975-06-25 American Cyanamid Co Topical steroid
US3980778A (en) * 1973-10-25 1976-09-14 The Upjohn Company Anti-inflammatory steroid
NL7502252A (nl) * 1974-02-27 1975-08-29 Pierrel Spa Werkwijze voor het bereiden van een geneesmid- del met anti-inflammatoire werking, gevormd ge- neesmiddel verkregen volgens deze werkwijze alsmede werkwijze voor het bereiden van in het geneesmiddel gebruikte nieuwe steroiden.
DE2655570A1 (de) * 1975-12-12 1977-06-16 Ciba Geigy Ag Neue polyhalogensteroide und verfahren zu ihrer herstellung
US4124707A (en) * 1976-12-22 1978-11-07 Schering Corporation 7α-Halogeno-3,20-dioxo-1,4-pregnadienes, methods for their manufacture, their use as anti-inflammatory agents, and pharmaceutical formulations useful therefor
US4081541A (en) * 1976-12-28 1978-03-28 Rorer Italiana S.P.A. Steroid derivatives
DE2735110A1 (de) * 1977-08-04 1979-02-15 Hoechst Ag Corticoid-17-alkylcarbonate und verfahren zu ihrer herstellung
JPS6040439B2 (ja) * 1978-03-29 1985-09-11 大正製薬株式会社 ヒドロコルチゾン誘導体
BE887518A (fr) * 1980-02-15 1981-08-13 Glaxo Group Ltd Cartothioates d'androstanes
DE3163871D1 (en) * 1980-07-09 1984-07-05 Draco Ab 1-(dihydroxyphenyl)-2-amino-ethanol derivatives; preparation, compositions and intermediates
US4298604B1 (en) * 1980-10-06 1998-12-22 Schering Corp Clotrimazole-betamethasone dipropionate combination
CY1359A (en) * 1981-02-02 1987-08-07 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
DE3133081A1 (de) * 1981-08-18 1983-03-10 Schering Ag, 1000 Berlin Und 4619 Bergkamen Neue 6(alpha)-methylprednisolon-derivate, ihre herstellung und verwendung
US4472392A (en) * 1983-01-21 1984-09-18 The Upjohn Company Sulfonate containing ester prodrugs of corticosteroids
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
CA1240708A (en) * 1983-11-15 1988-08-16 Johannes K. Minderhoud Process for the preparation of hydrocarbons
CA1261835A (en) * 1984-08-20 1989-09-26 Masaaki Toda (fused) benz(thio)amides
GB8607294D0 (en) * 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
US4826868A (en) * 1986-05-29 1989-05-02 Ortho Pharmaceutical Corporation 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use
US4783259A (en) * 1986-07-07 1988-11-08 Wade Charles E Helical coil filter element
CA1326662C (en) * 1988-03-09 1994-02-01 Yutaka Mizushima 11.beta.,17.,21-trihydroxy-1,4-pregnadiene-3,20-dione 21-[(e,e)-3,7,11-trimethyl-2,6,10-dodecatrienoate]
US5278156A (en) * 1988-03-09 1994-01-11 Kuraray Co., Ltd. 11-beta, 17-alpha, 21-trihydroxy-1, 4-pregnadiene-3, 20 21-[(E-E)-3,7, 11-trimethyl-2,6,10-dodecatrienoate]
GR1001529B (el) * 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
DK0548114T5 (da) * 1990-09-10 1995-01-30 Schering Corp Mometason-furoat-monohydrat, fremgangsmåde til fremtilling deraf og farmaceutiske præparater indeholdende dette
US5565473A (en) * 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
US6127353A (en) * 1991-09-06 2000-10-03 Schering Corporation Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
JP2818820B2 (ja) * 1993-11-26 1998-10-30 ファイザー・インク． 抗炎症剤としての３−アリール−２−イソオキサゾリン類
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
DZ1966A1 (fr) * 1995-02-06 2002-10-15 Astra Ab Combinaison pharmaceutique nouvelle.
US5976573A (en) * 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
US7122207B2 (en) * 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
US6727272B1 (en) * 2002-07-15 2004-04-27 Unitech Pharmaceuticals, Inc. Leflunomide analogs for treating rheumatoid arthritis
RU2387646C2 (ru) * 2003-08-29 2010-04-27 Рэнбакси Лабораториз Лимитед Ингибиторы фосфодиэстеразы типа-iv
US20080009535A1 (en) * 2004-08-30 2008-01-10 Sarala Balachandran Inhibitors of phosphodiesterase type-IV
ES2370788T3 (es) * 2005-02-07 2011-12-22 Aerocrine Ab Controlar flujo de aliento exhalado durante análisis.
DE102005044813A1 (de) * 2005-05-19 2007-10-04 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
AU2006305620A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
WO2007045979A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists

Also Published As

Publication number Publication date
WO2008035315A9 (en) 2008-10-23
MX2009003100A (es) 2009-05-11
WO2008035315A3 (en) 2008-12-04
CA2664247A1 (en) 2008-03-27
EP2086948A2 (en) 2009-08-12
JP2010504323A (ja) 2010-02-12
US20110021473A1 (en) 2011-01-27
CN101616901A (zh) 2009-12-30
WO2008035315A2 (en) 2008-03-27
KR20090069309A (ko) 2009-06-30
EA200900472A1 (ru) 2009-10-30
AU2007298549A1 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
US20110021473A1 (en) Inhibitors of phosphodiesterase type-iv
US10253019B2 (en) Tank-binding kinase inhibitor compounds
CA2704628C (en) Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
CN116568677A (zh) 可用于治疗mtap缺乏和/或mta累积癌症的哌啶-1-基-n-吡啶-3-基-2-氧代乙酰胺衍生物
US10077261B2 (en) Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer
US20100305093A1 (en) Inhibitors of mTOR and Methods of Making and Using
TW201925199A (zh) 對b型肝炎病毒(hbv)具有活性的新穎高活性吡唑并哌啶取代的吲哚-2-甲醯胺
US9102669B2 (en) Substituted piperidinyl-pyridazinyl derivatives useful as SCD 1 inhibitors
RS55165B1 (sr) Indazolil triazol derivati kao irak inhibitori
BR112014018868B1 (pt) composto heterocíclico aromático contendo nitrogênio, composição farmacêutica compreendendo dito composto e uso do mesmo
BR112020005174A2 (pt) composto que possui estrutura cíclica
KR20150135458A (ko) 신규한 피리딘 유도체
CN114585619A (zh) α-D-吡喃半乳糖苷衍生物
CN102459251A (zh) 作为白三烯a4水解酶的调节剂的具有两个稠合双环杂芳基部分的化合物
CA2755697A1 (en) Amide derivative
EP1958947A1 (en) Inhibitors of phosphodiesterase type 4
BRPI0609534A2 (pt) piperidinas 3,4,5-substituìdas
JP2011116716A (ja) アミン化合物
JP2011116705A (ja) 含窒素環状化合物
TW202225162A (zh) 芳香雜環類化合物、藥物組合物及其應用
HK40011511B (en) Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
HK40011511A (en) Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
HK1234051A1 (en) Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
HK1234051B (en) Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]